Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
An early study suggests that a common asthma drug may help treat hard-to-manage cancers, including aggressive breast cancers. The research indicates that blocking a specific protein could enhance the effectiveness of cancer immunotherapy. If confirmed, this finding could provide new options for patients resistant to current treatments.
- ▪The study focuses on the protein cysteinyl leukotriene receptor 1 (CysLTR1), which tumors may exploit to weaken immune responses.
- ▪Montelukast, an existing asthma medication, can block CysLTR1 and potentially reprogram immune cells to fight cancer more effectively.
- ▪The research highlights the role of neutrophils in cancer resistance to immunotherapy, suggesting a new therapeutic approach.
2 outlets in our directory ran this story, first to last over 23 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ A Common Asthma Drug May Help the Immune System Fight Cancer Again — Discover Magazine
Live Science files mainly under science. We currently carry 116 of its stories.
Opening excerpt (first ~120 words) tap to expand
Health Viruses, Infections & Disease Cancer Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models. By Marianne Guenot published 20 May 2026 in News When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Some cancers don't respond well to immunotherapy. An existing drug for asthma might help, research hints.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Live Science.
Discussion
0 commentsMore from Live Science
